Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. - Wikidata - awgldk - TriplyDB

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.

http://www.wikidata.org/entity/Q43613033

about

Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date Current and emerging medications for overweight or obesity in people with comorbidities Efficacy comparison of medications approved for chronic weight management Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.Naltrexone ER/Bupropion ER: A Review in Obesity Management.Clinical Management of Type 2 Diabetes Mellitus after Bariatric Surgery.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness.Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.Phenotypes of Obesity: How it Impacts Management.Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.Centrally Acting Agents for Obesity: Past, Present, and Future

P2860

Q27008813-107F4B8B-6C99-4483-A186-40D2BB781E80 Q27014110-645D7933-F04B-4BA2-AAB4-B15514BE4CDB Q28080825-712B5EC4-D46B-4C78-8B6B-5D0628C4ACA4 Q28081944-49775CF6-71C7-4A13-870A-7E85A639A309 Q37331171-ACD6F43F-DD6C-406E-B833-9C20C0AC77C4 Q37736845-63F669F0-6498-443D-B1BC-3C53E5212287 Q38536281-B02954A9-F789-4C4E-AA62-7DC939036F26 Q38572961-9F039981-334A-464A-B4BE-8E5B4AC8C166 Q38758765-97D9245B-A395-417A-B874-17FEA24FBDFA Q45070738-4BE34A2B-CFC3-4FDE-932F-470ADB899549 Q48042778-2BDCA554-12B5-45F6-955C-27E9355704D1 Q49834355-D02F254B-F757-4A37-972E-C56CCD68D170 Q52338665-56C878F8-45E1-4ECB-8540-3AE787BEA708 Q57177981-C4902D22-5570-4A9C-AAE0-BDE6EB0969FE

P2860

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.

http://www.wikidata.org/entity/Q43613033

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Combination therapy with naltr ...... total and visceral adiposity.

@en

Combination therapy with naltr ...... total and visceral adiposity.

@nl

type

label

Combination therapy with naltr ...... total and visceral adiposity.

@en

Combination therapy with naltr ...... total and visceral adiposity.

@nl

prefLabel

Combination therapy with naltr ...... total and visceral adiposity.

@en

Combination therapy with naltr ...... total and visceral adiposity.

@nl

P1433

Q43613033-910AA7FE-5E7B-43FF-A075-78BB9E6EF356

P1476

Q43613033-15AA9221-C0F7-42CD-B36A-64A5E9E0140E

P2093

Q43613033-002206B0-214D-4A7B-B398-524CEE9B95C0

Q43613033-25DF78EF-B49B-49D1-B495-7793610D01D2

Q43613033-29F1DDA3-F0F8-459E-A290-7C4EA2D2E6DA

Q43613033-3AC53145-B19F-4063-B236-84BE76DB23FF

Q43613033-43D94726-19FB-4476-BE52-E597959D0D7C

Q43613033-586481E9-C675-4748-BC88-D532F085D9DA

Q43613033-9FA3705A-485E-466B-B914-8FD45E7B124C

Q43613033-A68E2DFA-FB41-4201-845A-71103BBC096D

P2860

Q43613033-0C034B09-F423-4B6C-9B38-A0F99BC29F76

Q43613033-280FBC9A-60AC-4160-ADE2-CCBC4B4C6A66

Q43613033-3F7A2BF3-67B1-4799-B845-AC444A7C1A54

Q43613033-5617AD47-1A29-47CB-9639-DE87F4B932DA

Q43613033-80691EA4-EAE7-4C7F-9F65-BD89ACF215AF

Q43613033-9E985455-BA6D-4C3F-8801-677426EE7C61

Q43613033-BC958E28-2013-4862-96DB-2CD9E63C0D1D

Q43613033-C05022CD-829A-4F7C-BA07-AC08D75A2F4A

Q43613033-C1DBC4E0-CA85-468C-91E8-9D2E66EB134D

Q43613033-DBDD604A-E6EA-4DCA-92C6-CC3BB337DAF1

P304

Q43613033-5F5B09DF-2EF3-4F60-85C2-17C12EAC5162

P31

Q43613033-39394219-3D39-48FA-8E5A-7993B66EED4C

P356

Q43613033-41D31C60-45D0-4196-9F20-83DDF8D73C6F

P433

Q43613033-87858A22-6DB0-4F94-BA1B-0AF94423C31B

P478

Q43613033-B21E18CA-AA22-4D2A-9492-22C703AF8062

P577

Q43613033-AC9060BB-7F21-4476-BB0C-498152779892

P698

Q43613033-BA8E5533-D7B7-420D-A66D-C9F90080EF48

P921

Q43613033-23639848-F860-4EA5-ADC7-4B32B20B29E8

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Combination therapy with naltr ...... total and visceral adiposity.

@en

P2093

A K Gupta

http://www.w3.org/2001/XMLSchema#string

C Burns

http://www.w3.org/2001/XMLSchema#string

D Kim

http://www.w3.org/2001/XMLSchema#string

E Dunayevich

http://www.w3.org/2001/XMLSchema#string

F L Greenway

http://www.w3.org/2001/XMLSchema#string

K Fujioka

http://www.w3.org/2001/XMLSchema#string

S K Billes

http://www.w3.org/2001/XMLSchema#string

S R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

Efficacy of lifestyle modification for long-term weight control.

Abdominal obesity and metabolic syndrome.

Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review.

Diet-induced changes in intra-abdominal adipose tissue and CVD risk in American women.

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity.

Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial.

Mechanisms of metabolic fuel selection: modeling human metabolism and body-weight change.

P304

863-866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12095

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23489381

http://www.w3.org/2001/XMLSchema#string

P921